Segment Reporting - Reconciled to Consolidated Net Loss (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2025	Mar. 31, 2024
Segment Reporting [Abstract]
Revenue		$ 361	$ 640
Research and development expenses
Paltusotine		(16,491)	(12,952)
Atumelnant		(7,195)	(3,932)
Early research and development programs		(7,065)	(4,787)
Research and development personnel expenses		(27,473)	(18,427)
Research and development stock-based compensation		(11,819)	(7,565)
Other research and development	[1]	(6,197)	(5,678)
Total research and development expenses		(76,240)	(53,341)
Selling, general and administrative
External selling, general and administrative expenses		(14,041)	(7,185)
Selling, general and administrative personnel expenses		(12,826)	(7,754)
Selling, general and administrative stock-based compensation		(8,659)	(5,889)
Total selling, general and administrative expenses		(35,526)	(20,828)
Total other income, net		14,631	7,069
Loss on equity method investment		0	(470)
Net loss		$ (96,774)	$ (66,930)

[1] Other research and development is comprised of non-personnel related research and development indirect costs incurred for the benefit of multiple research and development programs, including depreciation, and other facility-based expenses, such as rent expense.